Cardiolife Expands to Australia Following Inclusion in the Australian Register of Therapeutic Goods

Cardiolife’s AI-powered ECG interpretation software has been included in the Australian Register of Therapeutic Goods (ARTG No. 524682), enabling the company to supply its technology in Australia and marking another step in its international growth.

The ARTG inclusion enables Cardiolife to support healthcare providers across Australia with AI-powered tools for the detection and diagnosis of cardiovascular conditions. The company’s software analyses ECG data to help clinicians improve diagnostic accuracy, consistency and efficiency in clinical practice.

“Australia is an important market with strong clinical standards and a clear focus on digital health,” said Kristin Lied, CEO of Cardiolife. “We are pleased to bring our technology to Australian clinicians and contribute to improved early detection and patient care.”

Cardiolife will now focus on establishing local partnerships and supporting the implementation of its solution in clinical settings across Australia.